<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Therapeutics</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6B6213D-3EDE-4C40-A6BE-6E8F2CB9048A"><gtr:id>B6B6213D-3EDE-4C40-A6BE-6E8F2CB9048A</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Hall</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400910"><gtr:id>FC2726CF-0947-47AC-9AAF-FF44556A8EF5</gtr:id><gtr:title>Defining the mechanisms underlying the physiological control of cyclic AMP signals in human airway smooth muscle</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400910</gtr:grantReference><gtr:abstractText>The applicant will continue to support public engagement in science through similar methods to those previously used by the applicants research group. These include presentation at appropriate meetings open to the lay public (eg research charity annual meetings for stakeholders), media presentation (this has included ITV regional news, BBC24, BBC regional news, local and national newspapers) and web based information using the new University of Nottingham portal (active from autumn 2004). The applicant has written a number of articles aimed at lay audiences for both local and national journals and magazines (eg the Asthma Journal) and has appeared on regional radio telephone answer slots. The applicant s group has also hosted students considering a career in science (eg we hosted 2 Nuffield bursary students in 2004).</gtr:abstractText><gtr:technicalSummary>Control of integrated cell cyclic AMP signals is a key regulatory mechanism governing airway smooth muscle contractility and hence airway calibre in conditions such as asthma. In this project we will use a combination of molecular biological and functional genetic approaches to gain a more complete understanding of the mechanisms underlying control of cell cyclic AMP breakdown in human airway smooth muscle following a2 adrenoceptor stimulation. Specifically we will:

a) Use transient expression of PKA CFP/YFP FRET probes to investigate regional PKA activation as a surrogate of cyclic AMP levels in primary cultured human airway smooth muscle cells under resting and stimulated conditions in order to determine whether or not compartmentalisation of PKA activation occurs under basal or different stimulated conditions. 

b) Investigate the ability of inhibitors of PDE isoforms (non specific e.g. IBMX, and isoform specific e.g. rolipram) to induce PKA activation in this system in order to define whether compartmentalisation of PKA activation accounts for the physiological effects of PDE inhibitors in these cells.

c) Use a combination of previously validated over expression/siRNA approaches to manipulate PDE4D5 expression specifically to address the contribution of PDE4D5 to regional control of cyclic AMP in human airway smooth muscle.

d) Study possible recruitment of PDE4D5 to the a2 adrenoceptor complex in human airway smooth muscle using constructs/ligands we have made, namely a PDE4D5 GFP fusion and fluorescent ligands and/or a red GFP receptor fusion.

e) Use luciferase based reporter gene approaches to address the functionality of polymorphic variation in the PDE4D gene promoters as a potential mechanism accounting for interindividual variability in response to PDE4 inhibition as a consequence of altered PDE4D splice form expression levels.</gtr:technicalSummary><gtr:fund><gtr:end>2009-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>206568</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of Massachussets</gtr:description><gtr:id>C220404D-193D-44DE-B98C-775E4F085EB7</gtr:id><gtr:impact>See output listed under G0701390</gtr:impact><gtr:outcomeId>0150AA77AB2-1</gtr:outcomeId><gtr:partnerContribution>New techniques acqured</gtr:partnerContribution><gtr:piContribution>Shared expertise resulting in new techniques in UK brought from USA and shared outputs</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School science visits</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>673E7524-EA7A-4243-A9B3-17EE54236CB4</gtr:id><gtr:impact>Named researcher (CB has visited local schools to discuss science with primary school children to different classes (class size ~30)

n/a as primary school setting</gtr:impact><gtr:outcomeId>L6XAr4aDNHc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIH workshop on airway smooth muscle</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0A814189-BD02-423A-BD1C-24530632628D</gtr:id><gtr:impact>NIH targeted workshop. Led to position statement on airway myocyte biology and new NIH funding call.

Supplement to Proc ATS, funding call from NIH</gtr:impact><gtr:outcomeId>49B95955A29</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Scientifique Nottingham (both junior and senior fora)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F7949206-7A8D-49A8-A85D-3CC60C117FF8</gtr:id><gtr:impact>Discussion at Cafe Scientifique meetings about mechanisms underlying asthma

None direct other than eductaion value</gtr:impact><gtr:outcomeId>789DE512AA8</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Capacity Building Studentship (Respiratory Research)</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E290DA30-3DB4-45B8-84D2-C80BCA2CC0B5</gtr:id><gtr:outcomeId>F411D0EA80D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>8716883C-BAA8-4598-A2D9-7E227EC903CF</gtr:id><gtr:outcomeId>503F1B17EA40</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MHRA review of LABA safety</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CB7C3E7C-6E41-47F8-80BA-94EBEC145BE8</gtr:id><gtr:impact>The review, to which I contributed, led to a national policy statement on LABA safety.</gtr:impact><gtr:outcomeId>E3WRZwZryoz</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D3860BDC-02F9-4F60-90A5-FD61868CD0F2</gtr:id><gtr:title>Clonally expanded human airway smooth muscle cells exhibit morphological and functional heterogeneity.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8e269fe7aa9301b7a60b253a54dc27e"><gtr:id>d8e269fe7aa9301b7a60b253a54dc27e</gtr:id><gtr:otherNames>Singh SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>5449202e3f0649.93938345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89A2684C-55FB-48FB-B31D-2E4D3260864D</gtr:id><gtr:title>A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8568a3bba5378fa6f462b628a756e972"><gtr:id>8568a3bba5378fa6f462b628a756e972</gtr:id><gtr:otherNames>Billington CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>90C2F01927B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31CCB51C-D23F-4BCD-962B-776127D51376</gtr:id><gtr:title>cAMP regulation of airway smooth muscle function.</gtr:title><gtr:parentPublicationTitle>Pulmonary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8568a3bba5378fa6f462b628a756e972"><gtr:id>8568a3bba5378fa6f462b628a756e972</gtr:id><gtr:otherNames>Billington CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1094-5539</gtr:issn><gtr:outcomeId>pm_15535_25_22634112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>088BED1C-C44A-43E8-A2F3-75C242F8383D</gtr:id><gtr:title>The role of inflammation resolution speed in airway smooth muscle mass accumulation in asthma: insight from a theoretical model.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24cf4e4a5662016da1e9f3c6d3383ea9"><gtr:id>24cf4e4a5662016da1e9f3c6d3383ea9</gtr:id><gtr:otherNames>Chernyavsky IL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5449202e0726e4.50910378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>479BC99C-0E1F-4E69-941A-608411FBBB1C</gtr:id><gtr:title>Salmeterol and cytokines modulate inositol-phosphate signalling in human airway smooth muscle cells via regulation at the receptor locus.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/157f8298cc7c85d4e6f6c2b50b86a78b"><gtr:id>157f8298cc7c85d4e6f6c2b50b86a78b</gtr:id><gtr:otherNames>Smith N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>E93B1B0BA99</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1ACCF4BE-DEC5-47F3-897F-967D8979A31A</gtr:id><gtr:title>Should we use ADRB2 variation to stratify asthma treatment?</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022db3eaa432db2d50da8b60d7b7a194"><gtr:id>022db3eaa432db2d50da8b60d7b7a194</gtr:id><gtr:otherNames>Hall IP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn><gtr:outcomeId>5449202d2721e6.40444584</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1AA9735-B064-424B-9BA5-3174A8C06FC0</gtr:id><gtr:title>Novel cAMP signalling paradigms: therapeutic implications for airway disease.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8568a3bba5378fa6f462b628a756e972"><gtr:id>8568a3bba5378fa6f462b628a756e972</gtr:id><gtr:otherNames>Billington CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>m74D4fzihya</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D8E4474-48CB-43F2-90A3-9F546C0D79CA</gtr:id><gtr:title>Real time analysis of ?(2)-adrenoceptor-mediated signaling kinetics in human primary airway smooth muscle cells reveals both ligand and dose dependent differences.</gtr:title><gtr:parentPublicationTitle>Respiratory research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8568a3bba5378fa6f462b628a756e972"><gtr:id>8568a3bba5378fa6f462b628a756e972</gtr:id><gtr:otherNames>Billington CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1465-9921</gtr:issn><gtr:outcomeId>mRhRDzmiETb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>066E272F-1B17-4357-BD6C-3DBC770C211B</gtr:id><gtr:title>Pharmacogenetic characterization of indacaterol, a novel beta 2-adrenoceptor agonist.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd75f8e784aaafe7f0dfeb2eaa4a0923"><gtr:id>cd75f8e784aaafe7f0dfeb2eaa4a0923</gtr:id><gtr:otherNames>Sayers I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>E8279D4AA03</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400910</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>